Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MNKD Mannkind Corp
- Stocks
- Healthcare
- NASDAQ: MNKD
Price (delayed)
$4.35
Market cap
$1.32B
P/E Ratio
43.5
Dividend/share
N/A
EPS
$0.1
Enterprise value
$1.56B
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its
Highlights
Mannkind's EPS has soared by 150% YoY
The equity has surged by 75% year-on-year and by 26% since the previous quarter
Mannkind's quick ratio has decreased by 43% YoY and by 29% QoQ
Key stats
What are the main financial stats of MNKD
Market
Valuations
Earnings
Shares outstanding
303.93M
Market cap
$1.32B
Enterprise value
$1.56B
Price to earnings (P/E)
43.5
Price to book (P/B)
N/A
Price to sales (P/S)
4.44
EV/EBIT
21.52
EV/EBITDA
18.92
EV/Sales
5.25
Revenue
$297.6M
Gross profit
$222.08M
Operating income
$78.16M
Net income
$30.12M
EBIT
$72.59M
EBITDA
$82.59M
Free cash flow
$21.82M
Per share
Balance sheet
Liquidity
EPS
$0.1
EPS diluted
$0.1
Free cash flow per share
$0.07
Book value per share
-$0.19
Revenue per share
$0.98
TBVPS
$1.33
Total assets
$410.14M
Total liabilities
$468.76M
Debt
$288.46M
Equity
-$58.62M
Working capital
$157.8M
Debt to equity
-4.92
Current ratio
2.36
Quick ratio
1.82
Net debt/EBITDA
2.91
Margins
Efficiency
Dividend
EBITDA margin
27.8%
Gross margin
74.6%
Net margin
10.1%
Operating margin
26.3%
Return on assets
7%
Return on equity
N/A
Return on invested capital
11.1%
Return on capital employed
24.7%
Return on sales
24.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MNKD stock price
How has the Mannkind stock price performed over time
Intraday
-1.58%
1 week
6.88%
1 month
-13%
1 year
-4.4%
YTD
-32.35%
QTD
-13.52%
Financial performance
How have Mannkind's revenue and profit performed over time
Revenue
$297.6M
Gross profit
$222.08M
Operating income
$78.16M
Net income
$30.12M
Gross margin
74.6%
Net margin
10.1%
The company's net margin has surged by 166% YoY and by 4.1% QoQ
MNKD's operating income has soared by 152% YoY and by 14% QoQ
MNKD's operating margin has surged by 91% year-on-year and by 9% since the previous quarter
Mannkind's gross profit has increased by 39% YoY and by 6% from the previous quarter
Price vs fundamentals
How does MNKD's price correlate with its fundamentals
Growth
What is Mannkind's growth rate over time
Valuation
What is Mannkind stock price valuation
P/E
43.5
P/B
N/A
P/S
4.44
EV/EBIT
21.52
EV/EBITDA
18.92
EV/Sales
5.25
Mannkind's EPS has soared by 150% YoY
The price to earnings (P/E) is 41% lower than the last 4 quarters average of 74.4
The equity has surged by 75% year-on-year and by 26% since the previous quarter
The P/S is 53% lower than the 5-year quarterly average of 9.6 and 24% lower than the last 4 quarters average of 5.9
The revenue has grown by 33% YoY and by 4.2% from the previous quarter
Efficiency
How efficient is Mannkind business performance
The company's return on invested capital has surged by 66% YoY and by 12% QoQ
Mannkind's ROS has increased by 39% YoY
The ROA is up by 13% QoQ
Dividends
What is MNKD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MNKD.
Financial health
How did Mannkind financials performed over time
The company's total assets is 13% lower than its total liabilities
Mannkind's quick ratio has decreased by 43% YoY and by 29% QoQ
The company's current ratio fell by 39% YoY and by 28% QoQ
The debt to equity has dropped by 123% year-on-year and by 34% since the previous quarter
The equity has surged by 75% year-on-year and by 26% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.